pixantrone has been researched along with Hematologic Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernareggi, A; Bowman, A; Byrne, B; Camboni, G; Dawson, LK; Jodrell, DI; Rye, R; Smyth, JF | 1 |
1 trial(s) available for pixantrone and Hematologic Diseases
| Article | Year |
|---|---|
A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Hematologic Diseases; Humans; Infusions, Intravenous; Isoquinolines; Middle Aged; Neoplasms; Tomography, X-Ray Computed | 2000 |